CHMP recommends Rinvoq to treat Crohns disease.- AbbVie
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Rinvoq.
The marketing authorisation holder for this medicinal product is AbbVie Deutschland GmbH & Co. KG. The CHMP adopted a new indication as follows: Crohn’s disease; Rinvoq is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.